Meta-analysis of 4 RCTs (2523 patients) with non-cystic fibrosis bronchiectasis: DPP-1 inhibitors vs placebo prolonged time to first exacerbation (HR 0.79) and increased the proportion exacerbation-free (RR 1.33), with no difference in quality of life scores.
Meta-analysisn = 2,523
Carvalhal et al. Exacerbation risk in patients with bronchiectasis receiving DPP-1 inhibitors vs placebo: A meta-analysis of RCTs